Basis: Evaluating Sirtuin Supplements To Benefit Elderly Trauma Patients (BES2T BET)

Status unconfirmed · Phase 1 · Has a placebo group

Conditions studied: Recovery of Function

In brief

Basis: Evaluating Sirtuin Supplements To Benefit Elderly Trauma Patients (BES2T BET) A phase I, randomized, double-blind, placebo-controlled, single institutional pilot trial investigating the impact of nicotinamide riboside/pterstilbene (BasisTM) on functional recovery after traumatic fall in elderly patients .

Key facts

Study ID

NCT03635411

Run by

Elysium Health

People needed

48

Starts

2018-12-06

Expected to finish

2020-12-01

Last updated by the study team

2020-01-06

Who can join

Age: 65 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• ≥ 65 year old
• Patient presenting to trauma bay

You may not qualify if…

• Currently taking medication for severe to moderate dementia (see Appendix 9)
• Currently taking niacin, nicotinic acid, nicotinamide, or nicotinamide riboside
• Pre-existing immobility (wheel chair or bed bound)
• Renal failure requiring hemodialysis or peritoneal dialysis
• End-stage Liver Disease (Model for End Stage Liver Disease Score ≥ 25) (see Appendix 11)
• Intubated prior to enrollment (excluding intubation for surgery)
• More than 48 hours post-injury
• Thoracic Anatomic Injury Score > 3 (see Appendix 10)
• Other Injuries with Anatomic Injury Score >2, excluding thorax (see Appendix 10)
• Hip fractures
• Non-English speaking

Where it is running

• Penn Presbyterian Medical Center — Philadelphia, Pennsylvania, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.